China has successfully developed recombination vaccines for the new coronavirus, and has begun clinical trials on March 16, CCTV News reported today.
A scientific research team led by Academician Chen Wei of the Military Medical Research Institute entered Wuhan last year and immediately started vaccine development.
Chen Wei said that according to international regulations and domestic regulations, vaccines have been prepared in advance for safety, effectiveness, quality control, and large-scale production.
For new coronaviruses, vaccines are the key to preventing the spread of the virus, so countries are developing corresponding vaccines.
A few days ago, a U.S. company announced that a new coronavirus vaccine has been put into phase I clinical trials. However, the vaccine was modified from the original vaccine for MERS virus. No new coronavirus samples were used.
Recombination vaccines refer to vaccines produced through genetic recombination mechanisms with the rapid development of genetics over the past two decades.
In order to solve the problems existing in traditional vaccines, reduce immunogenicity, improve safety, and reduce treatment time, people have proposed a new SIT method-immune recombinant vaccine.
With the development of molecular biology, cDNAs encoding most allergens have been discovered, and recombinant vaccines have gradually become a research hotspot in the treatment of allergic diseases.
Special Report: Fighting The New Coronavirus
More on Tech Industry
